Paraneoplastic thrombocytosis in ovarian cancer

New England Journal of Medicine

Volumn 366, Issue 7, 2012, Pages 610-618

  Stone, Rebecca L ^a   Nick, Alpa M ^a   McNeish, Iain A ^d   Balkwill, Frances ^d   Han, Hee Dong ^a   Bottsford Miller, Justin ^a   Rupaimoole, Rajesha ^a   Armaiz Pena, Guillermo N ^a   Pecot, Chad V ^a   Coward, Jermaine ^d   Deavers, Michael T ^a   Vasquez, Hernan G ^a   Urbauer, Diana ^a   Landen, Charles N ^e   Hu, Wei ^a   Gershenson, Hannah ^a   Matsuo, Koji ^a   Shahzad, Mian M K ^a   King, Erin R ^a   Tekedereli, Ibrahim ^a   Ozpolat, Bulent ^a   Ahn, Edward H ^f   Bond, Virginia K ^f   Wang, Rui ^b   Drew, Angela F ^g   Gushiken, Francisca ^a   Lamkin, Donald ^h,i   Collins, Katherine ^h   DeGeest, Koen ^i,j   Lutgendorf, Susan K ^h,i,j   Chiu, Wah ^b   Lopez Berestein, Gabriel ^a,a,c   Sood, Anil K ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UT Health ^*  (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e University of Alabama   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h E11 SSH   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; PACLITAXEL; SILTUXIMAB; THROMBOPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 84863115303     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1110352     Document Type: Article

References (27)

1. Leslie M. Cell biology: beyond clotting: the powers of platelets. Science 2010; 328:562-4.
2. Trousseau A, Bazire V, Cormack J. Lectures on clinical medicine, delivered at the Hôtel-Dieu, Paris. London: R. Hardwicke, 1867.
3. Riess L. Zur pathologischen anatomie des blutes. Arch Anat Physiol Wissensch Med 1872;39:237-49.
4. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med 1964;114:497-500.
5. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008;8:1247-55.
6. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006;354:2034-45.
7. Branehög I, Ridell B, Swolin B, Weinfeld A. Megakaryocyte quantifications in relation to thrombokinetics in primary thrombocythaemia and allied diseases. Scand J Haematol 1975;15:321-32.
8. Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17:6083-96.
9. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44. (Pubitemid 44175146)
10. Kluger HM, Chelouche Lev D, Kluger Y, et al. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res 2005;65:5578-87. (Pubitemid 40911158)
11. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13:7487-95.
12. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009;4:1670-80.
13. McFarland-Mancini MM, Funk HM, Paluch AM, et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 2010;184: 7219-28.
14. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359:2641-50. [Erratum, N Engl J Med 2010; 363:1877.]
15. Deng L, Broaddus RR, McCampbell A, et al. Identification of a novel estrogenregulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res 2005; 11:8258-64. (Pubitemid 41746935)
16. Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010;18:185-97.
17. Shahzad MM, Lu C, Lee JW, et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009;8:1027-34.
18. Lu C, Thaker PH, Lin YG, et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008;198(4):477.e1-477.e9.
19. Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12: 369-75. (Pubitemid 43166123)
20. Kaushansky KK. Thrombopoietin. N Engl J Med 1998;339:746-54.
21. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98:2720-5.
22. Burmester H, Wolber EM, Freitag P, Fandrey J, Jelkmann W. Thrombopoietin production in wild-type and interleukin-6 knockout mice with acute inflammation. J Interferon Cytokine Res 2005;25:407-13. (Pubitemid 41026262)
23. Blair P, Flaumenhaft R. Platelet alphagranules: basic biology and clinical correlates. Blood Rev 2009;23:177-89.
24. Ho-Tin-Noé B, Goerge T, Wagner DD. Platelets: guardians of tumor vasculature. Cancer Res 2009;69:5623-6.
25. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007;3:CD006652.
26. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
27. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20- year follow-up of five randomised trials. Lancet 2010;376:1741-50.